CCM-3
Cerebral cavernous malformations (CCMs) are sporadically acquired or inherited vascular lesions of the central nervous system consisting of clusters of dilated thin-walled blood vessels that predispose individuals to seizures and stroke. Mutations in CCM1, CCM2, or CCM3 lead to cerebral cavernous malformations, one of the most common hereditary vascular diseases of the brain. Endothelial cells within these lesions are the main disease compartments. Here, we show that adenoviral CCM3 expression inhibits endothelial cell migration, proliferation, and tube formation while down regulation of endogenous CCM3 results in increased formation of tube-like structures. Adenoviral CCM3 expression does not induce apoptosis under normal endothelial cell culture conditions but protects endothelial cells from staurosporine-induced cell death. Tyrosine kinase activity profiling suggests that CCM3 supports PDPK-1/Akt-mediated endothelial cell quiescence and survival (Schleider et al, Neurogenetics 12, 2011) .
Product Specifications
Synonyms
PDCD10; CCM3; TFAR15; programmed cell death 10
NCBI Gene ID
11235
UniProt
Q9BUL8
Accession Number
NP_009148.2
Accession Number mRNA
NM_007217.3
Chromosomal Location
3q26.1
Reactivity
Anti-Human
Cross Reactivity
Human
Target Antigen
Recombinant human CCM3 (RT #300-056)
Clone
Rabbit IgG
Applications
WB, IF
Purification Method
Protein A purified
Assay Protocol
Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.
Bioactivity
Western Blot: Use 1-5 µg/ml
Form
Lyophilized
Buffer
0.5X PBS, pH 7.2
Reconstitution
Water
Storage Conditions
Host or Source
Rabbit
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items